If you have rheumatoid arthritis, Crohn's disease, or psoriasis, you've probably heard of Humira, Remicade, or Enbrel. These are TNF-alpha inhibitors — biologic drugs that block a key inflammatory protein. The US tumor necrosis factor alpha inhibitors market report by MRFR shows that monoclonal antibodies are the largest drug class, but fusion proteins are the fastest‑growing. The market is $5.07 billion and will hit $7.15 billion by 2035, growing at 3.17% CAGR — steady, not explosive, because biosimilars are eating market share.

What's driving growth? Rheumatoid arthritis is the largest indication, but psoriasis is the fastest‑growing — as new data shows TNF inhibitors can clear skin completely. The US TNF-alpha inhibitors market analysis highlights that subcutaneous injection is the largest route of administration, but intravenous is the fastest‑growing — because some patients prefer less frequent dosing (every 4‑8 weeks).

What's new? Biosimilars (e.g., Amjevita, Cyltezo) are now widely available, cutting prices by 50‑80%. That's good for patients and insurers, but bad for originator sales. Also, oral TNF inhibitors are in development (e.g., Danilixin), which could be a game‑changer for needle‑phobic patients.

The bottom line: TNF inhibitors are a cornerstone of autoimmune therapy. If you're newly diagnosed, ask your rheumatologist about them. They're not cheap, but they work.